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Abstract
Background
Ketorolac has been associated with a lower risk of recurrence in retrospective studies, espe-
cially in patients with positive inflammatory markers. It is still unknown whether a single dose
of pre-incisional ketorolac can prolong recurrence-free survival.
Methods
The KBC trial is a multicenter, placebo-controlled, randomized phase III trial in high-risk
breast cancer patients powered for 33% reduction in recurrence rate (from 60 to 40%).
Patients received one dose of ketorolac tromethamine or a placebo before surgery. Eligible
patients were breast cancer patients, planned for curative surgery, and with a Neutrophil-to-
Lymphocyte Ratio�4, node-positive disease or a triple-negative phenotype. The primary
endpoint was Disease-Free Survival (DFS) at two years. Secondary endpoints included
safety, pain assessment and overall survival.
Findings
Between February 2013 and July 2015, 203 patients were assigned to ketorolac (n = 96) or
placebo (n = 107). Baseline characteristics were similar between arms. Patients had a
mean age of 55.7 (SD14) years.
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At two years, 83.1% of the patients were alive and disease free in the ketorolac vs.
89.7% in the placebo arm (HR: 1.23; 95%CI: 0.65–2.31) and, respectively, 96.8% vs. 98.1%
were alive (HR: 1.09; 95%CI: 0.34–3.51).
Conclusions
A single administration of 30 mg of ketorolac tromethamine before surgery does not
increase disease-free survival in high risk breast cancer patients. Overall survival difference
between ketorolac tromethamine group and placebo group was not statistically significant.
The study was however underpowered because of lower recurrence rates than initially antic-
ipated. No safety concerns were observed.
Trial registration
ClinicalTrials.gov NCT01806259.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended to improve pain control
in the perioperative period [1]. Beyond their analgesic role, some drugs of the NSAID family,
such as aspirin, may improve postoperative oncological outcomes [2, 3].
The biological effects of NSAIDs could be particularly relevant to the perioperative period,
as this period is marked by an activation of inflammatory pathways, which could contribute to
accelerated tumor growth and dissemination [4, 5]. In both animal models [6, 7] and retro-
spective studies [3, 8], perioperative administration of NSAID has been associated with
lower risk of cancer recurrence. Within the NSAID family, ketorolac—routinely used during
surgery—has been identified as one of the most interesting candidates to prevent recurrence
in breast, lung and ovarian cancer [3, 9–11].
In the breast cancer studies, this association was particularly noted in patients at high
risk of early recurrence, i.e. related to tumor-related factors (e.g. a triple-negative pheno-
type), signs of early dissemination (lymph-node invasion) and/or preoperative systemic
inflammation as measured by the neutrophil-to-lymphocyte ratio (NLR) [3, 10, 12]. The
NLR score has been proposed as a preoperative prognostic factor in multiple cancer types
[13] including breast cancer [14]. In our retrospective study, a high NLR was associated
with a higher risk of recurrence irrespective of the stage or of the type of breast cancer sur-
gery [15].
Ideally, the administration of ketorolac should be limited to the shortest possible period
[16], as the use of the intravenous route is limited to a few hours in case of one day surgery.
A single dose of ketorolac may also be acceptable for patients with relative contraindica-
tions, such as impaired renal function, respiratory contraindication or previous digestive
bleeding.
Consequently, a randomized, placebo-controlled, trial was designed to test the hypothesis
that a single intraoperative dose of ketorolac may be associated with a prolonged disease-free
survival after surgery in high risk breast cancer patients (NCT01806259) [15]. The primary
objective was to investigate the effect of perioperative ketorolac on disease-free survival (DFS)
at 2 years after breast cancer surgery.
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Patients and methods
Study design
The study was approved by the institutional review boards of all participating centers (central
ethics committee: Universite´ catholique de Louvain, Chairperson: Jean-Marie Maloteaux,
EUDRACT 2012-003774-76) and the study was conducted in accordance with the Declaration
of Helsinki and applicable national and European laws. Patients provided written informed
consent.
The KBCt trial was registered before patients enrollment (Principal investigator: Patrice
Forget, NCT01806259, date of registration: March 7, 2013). This is a Belgian, multicenter, pro-
spective, double-blind, placebo-controlled, randomized phase III trial in high risk breast can-
cer patients. Each patient was assigned to the ketorolac or the placebo group. Patients were
given one dose of ketorolac tromethamine (Taradyl1, N.V. Roche S.A., Belgium) or a match-
ing placebo. Each patient was randomly assigned on a 1:1 ratio to receive either 30 mg of ketor-
olac or a placebo during the induction of anesthesia (pre-incision). The placebo consisted of
NaCl 0.9% (3 mL) and was identically presented to ensure double blinding. No dose modifica-
tion was allowed because only one single dose was administered.
The standardized anesthetic protocol included: bolus followed by a continuous infusion of
propofol (as needed to maintain bispectral index value between 40 to 60 during the surgery),
ketamine 0.3 mg/kg, clonidine as needed to maintain hemodynamic stability (up to 4 μg/kg)
and sufentanil by boluses of 0.1 μg/kg as needed. Airways were instrumented by a laryngeal
mask airway. Postoperative analgesia included, for all the patients, the use of acetaminophen as
needed (3 to 4 g/day), tramadol 50 mg (and intramuscular piritramide 10 mg, a lipophilic mor-
phinomimetic with 0.7 of the potency of morphine, every 6 hours in the case of severe pain).
Neoadjuvant treatment, surgery and adjuvant treatment were done according to standard
practices at the participating centers. Follow-up was performed by the local oncologist, every 3
months after surgery for 2 years, then every 6 months for 3 years, and at least yearly thereafter.
Patients
Eligible patients were�18 and�75 years old with histologically or cytologically confirmed,
invasive ductal or lobular breast carcinoma planned for curative breast cancer surgery. In addi-
tion, to be considered high-risk, patients had to have one of the of 3 following criteria: (i) a
NLR�4 or (ii) node-positive disease (cN1-N3) or (iii) a triple-negative phenotype. The main
exclusion criteria were body weight below 50kg or above 100 kg, presence of any contra-indi-
cation to ketorolac, and a history of invasive cancer within the previous 5 years.
Randomization, endpoints and statistical analysis
Randomization of eligible patients was done the day before surgery and used randomization
blocks of 4. There was no stratification factor. In each center, a randomization list was kept
accessible exclusively to the pharmacist in charge of the preparation of the study product
(ketorolac or placebo). For each patient, a sealed opaque envelope was provided to permit
immediate unblinding in case of emergency.
The primary endpoint of the study was Disease-Free Survival (DFS) defined as time from
randomization to recurrence of invasive breast cancer; contralateral invasive breast cancer;
second non-breast malignancy; or death from any cause, whichever came first [17]. Secondary
endpoints were: overall survival (OS), loco-regional recurrence-free survival (LR-RFS), distant
metastasis recurrence-free survival (DM-RFS), safety (intra- & post-operative blood loss,
adverse events) and post-operative pain.
Ketorolac during breast cancer surgery
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Based on the retrospective study and other trials in the perioperative setting [18], the study
was designed to detect a 33% reduction in the risk of recurrence. With a power of 0.8 and an
alpha of 0.05, 100 high risk patients per group was then needed to detect a DFS increase from
40% to 60% at 2 years.
The intention-to-treat population was used for all efficacy analyses and per-protocol popu-
lation was used for sensitivity testing. Patients’ demographics, baseline characteristics (includ-
ing tumor characteristics and Nottingham Prognostic Index) and oncological treatments were
summarized using descriptive statistics (mean, standard deviation, median, minimum and
maximum values) for continuous parameters and frequencies and percentages for categorical
data. DFS and OS were estimated using the Kaplan-Meier method and compared between
groups by the Log-Rank test. Hazard Ratio (HR) comparing ketorolac with placebo and 95%
Confidence Intervals (CIs) were estimated from a Cox proportional hazards model. Safety
analyses included incidence of SAEs, intra- and postoperative bleeding. Treatment group com-
parisons were performed using Mann-Whitney test, Fisher or Chi-square as appropriate. All
statistical tests were 2-sided with a 5% Type I error.
All data were collected using REDCap (Research Electronic Data Capture System, Vander-
bilt University) and analyzed using SAS statistical software version 9.4 (Copyright, SAS Insti-
tute Inc.).
Results
Between February 2013 and July 2015, 203 patients from 4 sites in Belgium were randomly
assigned to ketorolac (n = 96) or placebo (n = 107) (Fig 1). A difference in patient numbers
appeared due to the use of a stratified randomization (by block, by centres).
The data cutoff for the primary efficacy analysis (DFS) was February 2018 with a median
follow-up of 26.9 months.
Patients’ characteristics
Patients’ characteristics are summarized in Table 1. Baseline characteristics were similar
between arms. Patients were considered at high risk of recurrence either because of a positive
clinical lymph node status (n = 152), because of a triple-negative phenotype (n = 40), because
of a NLR�4 (n = 28), or because of at least 2 of these criteria (TN & N+ (n = 10), TN & NLR
(n = 3), N+ & NLR (n = 4), all 3 criteria (n = 0)). Patients had a mean age of 55.7 (SD 14) years
ranging from 28 to 85. All were female except for 1 male in the ketorolac group. One patient
was included despite a metastasis at diagnosis (site) and was randomized to ketorolac. This
patient was included in all further analyses (intention-to-treat). All patients received the allo-
cated treatment and all underwent surgery after randomization.
Efficacy
After a median follow-up of 26.9 months, there was no difference in DFS (Fig 2) between
groups (HR, 1.23 with reference to Placebo; 95% CI, 0.65 to 2.31; p = 0.517). At two years,
83.1% of the patients were alive and disease free in the ketorolac group compared with 89.7%
in the placebo arm.
There was also no difference in OS (HR, 1.09; 95% CI, 0.34 to 3.51; p = 0.884), with 96.8%
of the patients who were alive after two years in the ketorolac vs. 98.1% in the placebo arm (Fig
3). Similarly, no difference was observed for LR-RFS (HR, 1.10; 95% CI,0.51 to 2.37; p = 0.816)
and DM-RFS (HR, 0.26; 95% CI, 0.74 to 3.01; p = 0.255).
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Safety
A summary of perioperative events relevant to ketorolac safety profile and of all serious
adverse events is presented in Table 2. There was one postoperative major bleeding in the
ketorolac arm that required surgical re-intervention, which resolved the event without the
need for blood transfusion. Both intra- and post-operative blood losses were not different
between groups (p = 0.063 and 0.114 respectively). There was no difference in pain at D1 after
surgery neither at rest (p = 0.620) nor in movement (p = 0.254).
Discussion
This study shows that a single administration of 30 mg of ketorolac tromethamine does not
improve disease-free survival in high-risk breast cancer patients. Overall survival is also com-
parable between the two groups. No safety concerns were raised in this study.
We selected patients known to carry a higher risk of recurrence, namely patients with a tri-
ple negative phenotype, patients with node involvement or patients with a high NLR. The
assumptions about the recurrence rate made when calculating the sample size were unfortu-
nately not respected, which led to our study being underpowered. However, the survival curves
are superimposable, which supports the conclusion of a lack of effect of a single administration
of ketorolac to prevent breast cancer recurrence.
What remains is that several studies indicates that inflammatory pathways are implicated in
postoperative cancer recurrences [5, 6, 19]. The surgical stress activates numerous pathways
known to promote tumor growth and one possible way to intervene is to use NSAIDs, like
ketorolac [20]. But, since nearly all anesthetic and analgesic drugs affect anticancer immunity
Fig 1. CONSORT diagram.
https://doi.org/10.1371/journal.pone.0225748.g001
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Table 1. Baseline characteristics of the patients, tumors, and treatments.
Characteristics Ketorolac
N = 96
Placebo
N = 107
Age, years
Mean (SD) 56.1 (14.0) 55.4 (13.9)
Range 30–85 28–85
Gender, N (%)
Female 95 (99%) 100 (100%)
Male 1 (1%) 0 (0%)
cT, N (%)
T1 29 (30%) 28 (26%)
T2 56 (58%) 63 (59%)
T3 11 (12%) 14 (13%)
Missing 0 (0%) 2 (2%)
cN, N (%)
N0 18 (19%) 23 (21%)
N+ 78 (81%) 83 (78%)
Missing 0 (0%) 1 (1%)
cM, N (%)
M0 92 (96%) 102 (95%)
M1 1 (1%) 3 (3%)
Missing 3 (3%) 2 (2%)
Histologic type(s), N (%)
Invasive ductal adenocarcinoma 80 (83%) 86 (80%)
Invasive lobular adenocarcinoma 15 (16%) 12 (11%)
Other 3 (3%) 8 (8%)
Histologic grade, N (%)
1 5 (5%) 11 (10%)
2 58 (60%) 52 (49%)
3 32 (33%) 42 (39%)
Missing 1 (1%) 2 (2%)
ER, N (%)
Positive 66 (69%) 77 (72%)
Negative 30 (31%) 29 (27%)
Missing 0 (0%) 1 (1%)
PR, N (%)
Positive 59 (62%) 65 (61%)
Negative 36 (37%) 42 (39%)
Missing 1 (1%) 0 (0%)
HER2/neu (IHC), N (%)
HER2- 79 (82%) 83 (77%)
HER2+ 17 (18%) 22 (21%)
Missing 0 (0%) 2 (2%)
Triple Negative, N (%)
Yes 22 (23%) 18 (17%)
No 74 (77%) 89 (83%)
NLR >4, N (%)
Yes 13 (14%) 15 (14%)
No 83 (86%) 92 (86%)
(Continued)
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and other tumor-promoting pathways (such as angiogenesis and VEGF) [21–23], ketorolac rep-
resents only one of the perioperative drug candidates to reduce the risk of recurrence [5, 24].
For instance, it could be that targeting both catecholamines and prostaglandins is necessary to
prevent the pro-metastatic processes induced by surgical stress as shown in preclinical experi-
ments in several models [25]. A clinical trial using propranolol—a non-selective beta-blocker—
and etodolac—an NSAID—in breast cancer patients provided encouraging biological results
but could not assess the impact of this approach on recurrence because of a limited size [26].
Bimodality in the relapse frequency over time in early stage breast cancer also remains a
reality [27]. An early peak, occurring in the first 18 postoperative months, has been observed
repeatedly in breast cancer patients [28–30] with particular relevance in patients with large
Table 1. (Continued)
Characteristics Ketorolac
N = 96
Placebo
N = 107
Chemotherapy, N (%)
Yes 80 (83%) 81 (76%)
No 16 (17%) 26 (24%)
If chemotherapy, type (%)
Adjuvant 27 (28%) 27 (25%)
Neoadjuvant 53 (55%) 54 (51%)
If chemotherapy, compound (%)
Antracyclins and taxanes 80 (83%) 79 (74%)
Missing 0 (0%) 2 (2%)
If Neoadjuvant chemotherapy, compound (%)
Antracyclins and taxanes 53 (55%) 53 (50%)
Missing 0 (0%) 1 (1%)
If Adjuvant chemotherapy, compound (%)
Antracyclins and taxanes 27 (28%) 26 (24%)
Missing 0 (0%) 1 (1%)
Type of surgery, N (%)
Mastectomy 60 (63%) 59 (55%)
Breast-conserving surgery 34 (35%) 48 (45%)
Missing 2 (2%) 0 (0%)
Type of lymphadenectomy, N (%)
None 6 (6%) 8 (8%)
Sentinel 5 (5%) 7 (6%)
Complete axillary 85 (89%) 91 (85%)
Missing 0 (0%) 1 (1%)
Post-operative radiotherapy, N (%)
Yes 77 (80%) 88 (82%)
No 19 (20%) 19 (18%)
Endocrine therapy, N (%)
Yes 69 (72%) 69 (64%)
No 27 (28%) 37 (35%)
Missing 0 (0%) 1 (1%)
If Endocrine therapy, compound (%)
Tamoxifen 40 (42%) 38 (36%)
Aromatase inhibitor 23 (24%) 27 (25%)
Tamoxifen before an aromatase inhibitor 6 (6%) 4 (4%)
https://doi.org/10.1371/journal.pone.0225748.t001
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tumor size, high histological grade, lymph node involvement or low expression of estrogen
receptors [12, 31]. However, the occurrence of the early peak is not here confirmed. Moreover,
a recent retrospective study found that the anticancer effect of ketorolac may be particularly
prominent in patients with a high Body Mass Index (BMI) [32]. However, we could not con-
firm this hypothesis in this prospective trial (data not shown), as no difference in outcomes
was observed when stratifying the analyses per BMI group (�25 vs.>25)—keeping in mind
that patients weighting more than 100 kg were excluded from the trial. Taken together, it
appears that new works are needed to investigate the patients’ subgroups that may specifically
benefit from intraoperative interventions during cancer surgery.
If a single dose of ketorolac has no impact on recurrence, it does not preclude an effect of a
longer administration. However, our choice of testing a single administration was partly sup-
ported by the increased risk of adverse events with prolonged administration of ketorolac [16].
Further studies with ketorolac may focus on the identification of relevant biomarkers, and its
effect on these biomarkers in specific patient subgroups. Because multiple biological pathways
are modulated by ketorolac (through the inhibition of both the COX-2 and the COX-1
enzymes [33] but also independently [11]), selecting a population more likely to benefit of a
longer administration of ketorolac might however be difficult.
In summary, these data do not support the use of a single administration of ketorolac before
breast cancer surgery to prevent breast cancer recurrence. To progress further, pivotal trials
Fig 2. Kaplan-Meier estimates of Disease-Free Survival (DFS) in the overall study population.
https://doi.org/10.1371/journal.pone.0225748.g002
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Fig 3. Kaplan-Meier estimates of Overall Survival (OS) in the overall study population.
https://doi.org/10.1371/journal.pone.0225748.g003
Table 2. Perioperative and adverse events.
Characteristics Ketorolac
N = 96
Placebo
N = 107
p-value
Perioperative events
Hospital stay, days
Mean (SD) 3.9 (1.2) 3.7 (1.0) 0.290
Range 1–8 2–7
Intra-operative blood loss, ml
Mean (SD) 188 (123) 176 (168) 0.063
Range 0–504 0–935
Postoperative blood loss in drains, ml
Mean (SD) 229 (217) 182 (164) 0.114
Range 0–1100 0–735
Postoperative major bleeding, N (%) 1 (1%)� 0 (0%) 0.473
Pain at rest at D1 after surgery Verbal simple scale (0–4), N (%) 0.620
0 18 (19%) 17 (16%)
1 35 (37%) 31 (29%)
2 37 (38%) 47 (44%)
(Continued)
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may be performed, focusing on the identification of relevant biomarkers, and the effect of
ketorolac on these biomarkers in specific patient subgroups.
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